Skip to content

Evaluation of the Translation of the DE-PLAN Program for the Primary Prevention of Type 2 Diabetes in Routine Primary Care

Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01365013
Acronym
DE-PLAN E
Enrollment
1113
Registered
2011-06-03
Start date
2011-06-30
Completion date
2015-07-31
Last updated
2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetic State

Keywords

Lifestyle, Prediabetic State, Patient Education, Primary Health Care

Brief summary

The purpose of this study is to evaluate the feasibility and effectiveness of the DE-PLAN Euskadi program for the primary prevention of type-II diabetes in high-risk population seen in primary care centers (Osakidetza-Basque Health Service) in which such intervention is implemented, compared to usual care control centers.

Detailed description

Objective: To evaluate the feasibility and effectiveness of the DE-PLANЄ program for the primary prevention of type-II diabetes in high-risk population seen in primary care centers (Osakidetza) in which such intervention is implemented, compared to usual care control centers. DESIGN AND METHODS: A phase IV cluster randomized prospective clinical trial, conducted in 14 primary care centers from Osakidetza, which will be randomly assigned to intervention or control group, that will collect a sample of 2534 followed for two years, aged 45 to 70 years without diabetes but with high risk of developing it (FINDRISC scale\> 14), identified by a screening system. Nurses in intervention centers (GI) will implement DEPLANЄ for 12 months, a structured educational intervention on healthy lifestyles (diet and physical activity), while patients of the control centers will receive standard care for the prevention and treatment of type-II diabetes. ANALYSIS: The feasibility will be reported as the reach, adoption and implementation of the program. The attributable effectiveness of the program will be determined by comparing the changes in the incidence and risk of developing diabetes in healthy habits quality of life, observed in patients exposed to DE-PLANЄ intervention and of patients from control centers. The incremental cost-utility of DE-PLANЄ program will be also analysed.

Interventions

BEHAVIORALDE-PLAN

structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year

BEHAVIORALControl group

Standard advice for lifestyle change

Sponsors

Basque Health Service
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 45 to 70 years old * high risk of developing type-II diabetes (Findrisc scale \> 14 points)

Exclusion criteria

* Disorders of the cardiovascular system * Transplant recipients * Renal or hepatic failure * Severe chronic obstructive pulmonary disease * Severe mental disorders * Chronic and acute severe infections * Metabolic uncontrolled disorders * Restrictive pathology of muscles, bones and joints * Complicated pregnancy * Contact difficulties

Design outcomes

Primary

MeasureTime frameDescription
Adoption of healthy lifestyles12 monthsChange in the adoption of minimum recommended levels of physical activity and fruit and vegetable consumption
Incidence of Diabetes24 monthsEffectiveness of the program in the reduction of the Incidence of Diabetes

Secondary

MeasureTime frameDescription
Reach of the program24 monthsPercentage of eligible participants exposed to the program
Implementation of the program24 monthsExtent in which the intervention components have been delivered as intended (intervention protocol)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026